- Home
- BLKB vs VRDN Comparison
BLKB vs VRDN Comparison
Compare BLKB & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLKB | VRDN |
|---|---|---|
| Founded | 1981 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | 2004 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLKB | VRDN |
|---|---|---|
| Price | $63.51 | $32.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $70.50 | $39.00 |
| AVG Volume (30 Days) | 343.2K | ★ 1.6M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,136,093,000.00 | $70,789,000.00 |
| Revenue This Year | N/A | $26,477.48 |
| Revenue Next Year | $4.09 | $6.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 23340.07 |
| 52 Week Low | $54.56 | $9.90 |
| 52 Week High | $83.20 | $33.34 |
Technical Indicators
Market Signals| Indicator | BLKB | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 61.50 | 65.86 |
| Support Level | $55.88 | $30.22 |
| Resistance Level | $58.00 | $33.49 |
| Average True Range (ATR) | 1.87 | 1.20 |
| MACD | 0.94 | -0.01 |
| Stochastic Oscillator | 86.90 | 74.81 |
Price Performance
Historical ComparisonAbout BLKB Blackbaud Inc.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).